500660 Stock Overview
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
NewNotes are coming soon
GlaxoSmithKline Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,262.95 |
| 52 Week High | ₹1,734.90 |
| 52 Week Low | ₹1,260.00 |
| Beta | 0.17 |
| 1 Month Change | -5.07% |
| 3 Month Change | -8.38% |
| 1 Year Change | -22.71% |
| 3 Year Change | -24.53% |
| 5 Year Change | 3.13% |
| Change since IPO | 973.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500660 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.7% | -2.0% | -1.9% |
| 1Y | -22.7% | -3.4% | 2.9% |
Return vs Industry: 500660 underperformed the Indian Pharmaceuticals industry which returned -5.1% over the past year.
Return vs Market: 500660 underperformed the Indian Market which returned 1.9% over the past year.
Price Volatility
| 500660 volatility | |
|---|---|
| 500660 Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: 500660 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: 500660's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 3,840 | Bhushan Akshikar | https://india-pharma.gsk.com |
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands.
GlaxoSmithKline Pharmaceuticals Limited Fundamentals Summary
| 500660 fundamental statistics | |
|---|---|
| Market Cap | ₹213.95b |
| Earnings (TTM) | ₹3.94b |
| Revenue (TTM) | ₹32.88b |
54.3x
P/E Ratio6.5x
P/S RatioIs 500660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500660 income statement (TTM) | |
|---|---|
| Revenue | ₹32.88b |
| Cost of Revenue | ₹13.46b |
| Gross Profit | ₹19.42b |
| Other Expenses | ₹15.48b |
| Earnings | ₹3.94b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 07, 2023
| Earnings per share (EPS) | 23.26 |
| Gross Margin | 59.07% |
| Net Profit Margin | 11.98% |
| Debt/Equity Ratio | 0% |
How did 500660 perform over the long term?
See historical performance and comparison